7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Key facts

Sponsor

QOL Medical, LLC

Principal Investigator

Weng Tao, M.D., Ph. D

QOL Medical

Intervention

Sucraid (sacrosidase) Oral Solution 8500 IU/mL(biological)

Enrollment

312 enrolled

Eligibility

17 years · All sexes

Timeline

2022 – 2024

Study locations (20)

• Children's Hospital Los Angeles, Los Angeles, California, United States
• UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
• Kidz Medical, Coral Gables, Florida, United States
• Orlando Health, Orlando, Florida, United States
• Children's Healthcare of Atlanta, Atlanta, Georgia, United States
• Center for Digestive Health Care, LLC, Atlanta, Georgia, United States
• University of Maryland Baltimore, Baltimore, Maryland, United States
• Johns Hopkins University, Baltimore, Maryland, United States
• GI Associates, Flowood, Mississippi, United States
• Happy Tummies, Flowood, Mississippi, United States
• Children's Mercy Hospital, Kansas City, Missouri, United States
• Atlantic Health System, Morristown, New Jersey, United States
• WNY Pediatric Gastroenterology, Buffalo, New York, United States
• University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
• Measurable Outcomes Research, Oklahoma City, Oklahoma, United States
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Congenital sucrase-isomaltase deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07309601
  Sucrase-Isomaltase (SI) Genes and Meal Load
  Region Skane

See all trials for Congenital sucrase-isomaltase deficiency →